Breaking AI & Tech News Analyzed

Researchers have made a significant breakthrough in understanding why weight-loss medications, such as GLP1 receptor agonists, work better for some individuals than others. A recent study published in Nature has identified genetic variations in two genes involved in gut hormone pathways that regulate appetite and digestion. These genetic variations may help account for different weight-loss results or side-effects when taking glucagon-like peptide 1 (GLP1) medicines, which mimic natural gut hormones to regulate appetite, insulin release, and digestion. The study analyzed data from 27,885 patients on GLP1 drugs and found that specific genetic variants were associated with slightly more weight loss or side-effects like nausea and vomiting. The findings suggest that genetic differences may contribute to why people respond differently to weight-loss jabs. However, the overall impact of genetics appeared to be modest, with non-genetic factors such as sex, drug type, dose, and duration appearing to explain a substantially larger proportion of variability. The study's results reinforce that while there is substantial variability in response to GLP1 therapies, genetics is only one part of a much more complex picture. According to Marie Spreckley, an obesity expert at the University of Cambridge, the study provides plausible evidence that genetic variants could affect outcomes. However, she notes that the magnitude of these genetic effects is small in clinical terms, and that behavioral, clinical, and treatment-related factors remain the dominant drivers of outcomes. The study's authors suggest that their findings could support future efforts to use genetic information when making treatment choices for obesity. However, Spreckley cautions that the evidence is not yet sufficient to support using genetic information to guide treatment decisions in routine clinical practice.

Researchers at Rothamsted Research in Harpenden, Hertfordshire, have made a groundbreaking discovery in the field of food safety. By utilizing Crispr genome editing, they have successfully developed wheat that can be used to make bread with reduced levels of acrylamide, a toxic compound classified as a probable carcinogen.The innovation lies in the reduction of free asparagine, an amino acid in wheat that converts into acrylamide when bread is toasted, fried, or baked. Field trials over two years demonstrated that gene-edited wheat can have significantly lower concentrations of free asparagine without impacting crop yields. This translates into lower acrylamide formation in food products, making toasted bread safer for consumption.In tests, bread and biscuits made from the edited wheat showed substantially reduced acrylamide levels, with some bread samples having concentrations below detectable limits even after toasting. The Crispr editing targeted the gene responsible for asparagine production, achieving a reduction of up to 93% in free asparagine in dual-edited lines.Compared to conventional methods that achieved a 50% reduction in free asparagine but resulted in a 25% yield penalty, the Crispr-edited wheat offers a more efficient and effective solution. Dr. Navneet Kaur, a lead researcher, highlighted the potential of Crispr technology to deliver precise, beneficial changes in crop genetics, emphasizing the importance of supportive regulatory frameworks to unlock benefits for agriculture and food systems.The UK has become a global hub for gene editing research since Brexit, with the Genetic Technology (Precision Breeding) Act of 2023 facilitating the development and marketing of genetically modified crops. However, the future of these advancements may be influenced by negotiations with the EU over sanitary and phytosanitary agreements.Prof. Nigel Halford, who led the study, noted that low-acrylamide wheat could help food businesses meet safety standards without compromising product quality or incurring major costs, ultimately reducing consumers' dietary exposure to acrylamide.

Cooper Lutkenhaus, a 17-year-old American high school student, has taken the athletics world by storm by becoming the youngest world champion in track and field history. He achieved this incredible feat by winning the 800m indoor world championship in Torun, Poland.Lutkenhaus's remarkable talent has drawn comparisons to top athletes like David Rudisha, with Belgian athlete Eliott Crestan saying, 'He's like David Rudisha... In 10 or 20 years' time, I'll be able to say that I ran against him.'The young athlete's coach, Chris Capeau, attributes his success to a combination of 'God's gifts, his mum and dad's genetics, and his upbringing.' Capeau also highlights Lutkenhaus's intense focus on detail and his ruthless approach to maximizing his potential.Lutkenhaus's achievements have made him a sensation in the athletics world, with many eagerly anticipating his future performances, including his participation in the Eugene and Stockholm Diamond League this summer.Despite his remarkable success, Lutkenhaus remains humble and grounded, celebrating his gold medal with a simple burger and fries with his family. His father, George, emphasizes the importance of allowing his son to enjoy the moment and not getting caught up in the hype surrounding his achievements.

Caster Semenya, the two‑time Olympic 800‑metre champion, has pledged to fight the International Olympic Committee’s (IOC) newly announced gender‑testing policy that would apply to all female athletes competing in strength, power or endurance events. The South African athlete says the rule "undermines women’s rights" and lacks scientific justification. The IOC unveiled the policy last week, stating that including “androgen‑sensitive XY‑DSD athletes” in the female category "runs fundamentally counter to ensuring fairness, safety and integrity in elite competition." The measure is expected to become a universal requirement across Olympic sports, replacing a patchwork of national regulations that have sparked controversy for years. Semanya, who has been embroiled in a long‑running legal dispute with World Athletics over her right to compete despite having a Difference of Sexual Development (DSD), told Reuters, "We’re going to be vocal about it, we’re going to make noise until we’re heard". She added, "Enough is enough – women will not be told how to compete". DSDs are rare conditions involving variations in genes, hormones and reproductive anatomy. Some individuals with DSDs are raised as female yet possess XY chromosomes and testosterone levels typical of males. The IOC’s testing protocol will involve a cheek‑swab or saliva sample to detect the SRY gene on the Y chromosome, with further investigation for any positive results. Semanya rejected the scientific premise of the rule, stating, "There’s no science that XY‑DSD gives an athlete an advantage". She emphasized that athletic success stems from hard work, not genetics, and criticized those who claim intersex conditions confer a performance edge. She also criticized IOC President Kirsty Coventry, the first woman and first African to hold the position, for failing to consult athletes with DSDs before issuing the policy. "They sent us a letter the day they were going to publish the new policy," Semanya said, urging genuine stakeholder engagement rather than a perfunctory "tick‑the‑box" approach. By labeling the policy as a breach of women’s dignity and rights, Semanya aims to rally broader support for intersex athletes and challenge what she describes as a historically flawed testing regime.

The United Kingdom's growing fascination with doodle breeds may require reconsideration following new research indicating that certain designer crossbreed dogs display more behavioral problems than their purebred ancestors.Crossbreeds between poodles and other canine varieties have surged in popularity across the UK, driven by the belief that these dogs will be hypoallergenic, healthy, and child-friendly.However, the study published in Plos One has discovered that cockapoos (cockerspaniel-poodle mixes) and cavapoos (cavalier king charles spaniel-poodle mixes) demonstrate more undesirable behaviors than their respective purebred parent breeds.The research team, led by scientists at the Royal Veterinary College, analyzed comprehensive data from 3,424 crossbreed and 5,978 purebred dogs through owner questionnaires focusing on cockapoo, labradoodle, cavapoo, cocker spaniel, labrador retriever, cavalier king charles spaniel, and poodle owners.The questionnaire assessed owner demographics, expectations, training methods, and included 73 behavioral questions that generated ratings across 12 different behavior scales.Cockapoos exhibited significantly more problematic behaviors than poodles on six different scales, including owner-directed aggression, stranger-directed aggression, dog rivalry, non-social fear, separation-related problems, and excitability.When compared to cocker spaniels, cockapoos additionally showed increased undesirable behaviors in dog-directed aggression, stranger-directed fear, dog-directed fear, and trainability.Cavapoos demonstrated different behavioral patterns compared to poodles on three scales and performed worse than cavalier king charles spaniels on eight of the nine scales where differences were observed.Labradoodles showed better behavioral scores than poodles across all six differing scales but performed worse than labradors on all five scales where differences were found.Professor Daniel Mills of the University of Lincoln, not involved in the study, emphasized that behavior results from the complex interaction between genetics and environment. He noted that cultural factors, including differences in owner behavior and training approaches between breeds, likely contribute significantly to the observed variations.The study authors recommend that potential dog owners should thoroughly investigate breed characteristics during pre-purchase research to avoid making uninformed decisions about breed selection.